论文部分内容阅读
在心肌的离子通道研究中,至今已发现L、T、B三型钙离子通道,其中,L型钙通道在心肌中的存在及其理要意义早已得到公认,L型钙通道阻滞剂在过去的二十年中广泛应用于心血管疾病的治疗;B型钙通道为自发性开放通道,其电流是心肌钙电流的背景成分;而心肌的另一型钙通道—T型钙通道的发现较晚,但随着研究的深入,人们发现T型钙通道在心血管系统中同样扮演着重要的角色,其特异性阻滞剂Mibefradil更是表现出L型钙通道所不具备的优点,有望成为治疗多种心血管疾病的理想药物。本文就近年来T型钙通道的生理、病理生理及其阻滞剂Mibefradil方面的研究进展作一综述。
In myocardial ion channel studies, so far have been found L, T, B three types of calcium ion channels, of which, L-type calcium channels in the myocardium and its significance has long been recognized, L-type calcium channel blockers in Over the past two decades, it has been widely used in the treatment of cardiovascular diseases. Type B calcium channel is a spontaneous open channel whose current is the background component of myocardial calcium current. The discovery of T type calcium channel, another type of calcium channel in myocardium, Later, but with the deepening of research, people found that T-type calcium channels also play an important role in the cardiovascular system, and its specific blocker Mibefradil more shows the advantages of L-type calcium channels are not expected to become Ideal for the treatment of many cardiovascular diseases. This review summarizes the recent advances in the physiological, pathophysiology of T-type calcium channels and its blocker Mibefradil.